Earnings ·
Reports Q3 net revenue of $286.0 million and raises full-year ARCALYST sales guidance to $1.045-$1.050 billion
KNSAKiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International reported third-quarter 2026 total revenue of $286.0 million, driven by a ~58% year-over-year increase in net product revenue for its ARCALYST franchise. The company posted net income of $47.3 million and raised its full-year 2026 ARCALYST net product revenue guidance to between $1.045 billion and $1.050 billion, up from the previous range of $980 million to $995 million. The biopharmaceutical company is developing and commercializing novel therapies for cardiovascular indications.